AWS is both Amazon's largest segment by profitability and its fastest-growing. The segment saw its revenue growth accelerate in the quarter, with AWS revenue climbing 24% to $35.58 billion. It was the ...

DraftKings missed the mark with its guidance for this year as it plans steep investments in prediction markets. The lines between sports betting and prediction markets are already blurry, but ...

Micron's earnings popped by 167% year over year in its fiscal first quarter, and its gross margins continued to expand. Demand for its memory chips could push prices higher this year. Alphabet and ...

Looking ahead to 2030, our model projects RIVN could trade at an average price of $25.01, with a potential range between $18.76 and $31.27. This represents a potential 62.7% return from today's price.

That was the estimated weekly trading volume on prediction-market platforms Polymarket and Kalshi last week, according to a team of analysts at Piper Sandler. It’s a new record. Prediction markets got ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Most investors looking to capitalize on the artificial intelligence (AI) craze start their search with a familiar name like Nvidia, Microsoft, or Alphabet. And understandably so. These companies are ...

Investors sold shares of chipmaker AMD following its fourth-quarter report last week. Its P/E ratio remains high, and its Q1 guidance came in slightly below some investors' expectations. The growth ...

Harley-Davidson HOG-2.12%decrease; red down pointing triangle more than doubled its loss in the fourth quarter as motorcycle sales continued to slump. The motorcycle maker on Tuesday recorded a ...

Looking ahead to 2030, our model projects WMT could trade at an average price of $162.00, with a potential range between $121.50 and $202.50. This represents a potential 30.9% return from today's ...

Shares of Hims & Hers plunged 19% on Monday afternoon after the U.S. company quickly reversed plans to introduce its own compounded version of Novo Nordisk’s Wegovy oral weight-loss drug. After the ...